

**ABSTRACT**

Glycopeptide comprising 1 to 40 repeated C-terminal polypeptides, with 11 amino acids, of BSDL or FAPP, whereby said polypeptides are glycosylated and bear glycosylated epitopes giving rise to a specific immunological reaction with induced antibodies in a patient suffering from type 1 diabetes and/or purified from biological fluids of human or animal origin or recombinant and produced by expression in a standard host cell comprising an enzymatic material necessary for priming a glycosylation, said host cell being genetically modified such as to comprise a gene coding for said polypeptides and a gene coding for one or more enzymes selected from among glycosyltransferases, anti-glycopeptide antibodies and the applications thereof in therapeutics and diagnostics.